Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.39 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2799266 | 0.89 | KDM4E (0.43) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL2175823 | 0.81 | CYP3A4 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL1878352 | 0.80 | CHRNA7 (0.39) | CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL2797723 | 0.75 | KDM4E (0.50) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL2179678 | 0.73 | HTR2C (0.38) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL12490670 | 0.72 | KDM4E (0.40) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL9670354 | 0.71 | MEN1 (0.43) | KDM4EALDH1A1CYP1A2CYP3A4MAPT | |
| SCHEMBL15242149 | 0.70 | CHRNA7 (0.33) | CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL2180140 | 0.70 | CYP1A2 (0.50) | CHRNA7CHRNA10CHRNA9KDM4EALDH1A1 | |
| SCHEMBL14465889 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629163-B2 | Tetrakis-quaternary ammonium salts and methods for modulating neuronal nicotinic acteylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629163-B2 | Tetrakis-quaternary ammonium salts and methods for modulating neuronal nicotinic acteylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629163-B2 | Tetrakis-quaternary ammonium salts and methods for modulating neuronal nicotinic acteylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130231366-A1 | Use of a Novel Alpha-7 Nachr Antagonist to Suppress Pathogenic Signal Transduction in Cancer and Aids | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231366-A1 | Use of a Novel Alpha-7 Nachr Antagonist to Suppress Pathogenic Signal Transduction in Cancer and Aids | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231366-A1 | Use of a Novel Alpha-7 Nachr Antagonist to Suppress Pathogenic Signal Transduction in Cancer and Aids | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2013-09-05 | — | — | US | disclosed |
| US-20100179186-A1 | USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100179186-A1 | USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100173937-A1 | USE OF TETRAKIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173937-A1 | USE OF TETRAKIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-20090143424-A1 | TETRAKIS-QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACTEYLCHOLINE RECEPTORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143424-A1 | TETRAKIS-QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACTEYLCHOLINE RECEPTORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179186-A1 | USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS | CHRNA7, CHRNG, CHRNE | CHRNB2 16/4885CHRNB4 15/4885CHRNA3 14/4885 |
| US-20130231366-A1 | Use of a Novel Alpha-7 Nachr Antagonist to Suppress Pathogenic Signal Transduction in Cancer and Aids | CHRNA7, CHRNG, CHRNE | CHRNB2 16/4885CHRNB4 15/4885CHRNA3 14/4885 |
| US-20100173937-A1 | USE OF TETRAKIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | CACNA1I, TRPA1, KCNN3 | CHRNB2 353/4885CHRNB4 373/4885CHRNA3 233/4885 |
| US-20090143424-A1 | TETRAKIS-QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACTEYLCHOLINE RECEPTORS | CHRNA3, CHRNA2, CHRNA4 | CHRNB2 11/4885CHRNB4 12/4885CHRNA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.